Introduction
Multiple myeloma (MM) is an incurable plasma cell (PC) neoplasm characterized by the displacement of physiological hematopoiesis, the presence of osteolytic bone lesions and impairment of renal function due to the accumulation of malignant PC in the bone marrow and the production of monoclonal protein.
Almost all MM cells (MMC) show an aberrant or overexpression of a D-type cyclin, . cyclin D1 (CCND1) in the case of a t( ; )
i.e 11 14 translocation or gain of 11q13, cyclin D3 (CCND3) overexpression in case of the rare t( ; ) translocation, or an overexpression of cyclin 6 14 D2 (CCND2) on the background of a translocation involving (t( ; )) or (t( ; )) ( ). During the course of the disease, c-maf 14 16 FGFR3 4 14 1-3 further cytogenetic aberrations accumulate( ). Still, survival of MMC depend on the autocrine and paracrine stimulation by growth factors, 4 like interleukin-6 (IL-6) ( ), interferon alpha ( ), insulin-like growth factor ( ), hepatocyte growth factor ( , ), members of the EGF 5 6 7 8 9
family ( ) and members of the TNF-family ( , ) From the latter, we and others have recently shown that BAFF (B-cell activating 10-12 13 14 factor, also called BLys) and APRIL (A Proliferation-Inducing Ligand) are potent MMC growth factors ( , ). BAFF binds to 3 15 16 receptors -BAFF-R, BCMA and TACI -, and APRIL binds to BCMA and TACI ( ). 17
The activation of nuclear factor (NF)-B by TACI, BCMA and BAFF-R( ) is consistent with the antiapoptotic role of BAFF since κ B and PI3K/AKT pathways confirming our previous results. Furthermore, they showed BAFF could activate the canonical and the non canonical NF B pathways in MMC. 
Materials and methods

Cell samples
XG-1, XG-2, XG-3, XG-4, XG-5, XG-6, XG-7, XG-10, XG-11, XG-12, XG-13, XG-16, XG-19, and XG-20 human myeloma cell lines (HMCL) were obtained and characterized in our laboratory ( ). SKMM, OPM2, LP1 and RPMI8226 were purchased from 26-29 ATTC (Rockville, MD). Normal bone marrows were obtained from healthy donors after informed consent was given and BMPC were purified using anti-CD138 MACS microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) as described ( ). Polyclonal 25 plasmablasts were generated by differentiating peripheral blood CD19 B cells ( ).
+ in vitro 30
Flow cytometry analysis
The expression of TACI on HMCLs was evaluated by incubating 5 10 cells with an anti-TACI monoclonal antibody (MoAb) 
Modulation of the gene expression profile by addition or deprivation of BAFF/APRIL in MMC
The modulation of gene expression by addition of BAFF and APRIL was investigated with the XG-7, XG-13 and XG-20 HMCL.
XG-7, XG-13 and XG-20 cells were starved of IL-6 for 3 hours and washed. Then BAFF (Peprotech, Rocky Hill, NJ) and APRIL (R&D Systems, Abington, UK) (200 ng/mL each) were added in one culture group for 12 hours in RPMI1640/10 FCS. The modulation of gene % expression by deprivation of BAFF/APRIL in RPMI8226 and LP1 HMCL was also investigated. RPMI8226 and LP1 HMCL were starved for 3 hours and washed. Then TACI-Fc (R&D Systems) (10 g/mL) was added in one culture group for 12 hours in RPMI1640/10 FCS.
μ % RNA were extracted for gene expression profiling or real-time PCR analysis.
Modulation of the gene expression profile after NF-kappaB pathway inhibition
To investigate the modulation of gene expression by NF-kappaB pathway inhibition, RPMI8226 and LP1 cells were cultured for 12
hours with an inhibitory peptide of NF-kappaB pathway (100 g/ml, SN50) or the corresponding inactive peptide (BIOMOL, Plymouth Preparation of complementary RNA (cRNA) and microarray hybridization RNA was extracted using the RNeasy Kit (Quiagen, Hilden, Germany). Biotinylated cRNA was amplified with a double in vitro transcription and hybridized to the Affymetrix HG U133 set microarrays, according to the manufacturer s instructions (Affymetrix, Santa okadaic acid. Lysates were cleared by centrifugation at 10,000 for 10 min and resolved by 10 sodium dodecyl sulphate polyacrylamide g % gel electrophoresis (SDS-PAGE) before transfer to a nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). Membranes were blocked for 1 hour at room temperature in 140 mM NaCl, 3 mM KCl, 25 mM tris-HCl (pH 7.4), 0.1 Tween 20 (TBS-T), 5 BSA, % % then incubated for 3 hours at room temperature with anti-c-maf MoAb (Abnova, Taiwan) at a 1:1000 dilution in 1 BSA TBS-T. The % primary antibodies were visualized with goat anti-rabbit (Sigma) or goat anti-mouse (Bio-Rad, Hercules, CA) peroxidase-conjugated antibodies using an enhanced chemiluminescence detection system. As a control for protein loading, we used anti-Beta actin (1:2000)
(Santa Cruz Biotechnology, Santa Cruz, CA) antibody.
siRNA transduction
The siRNA duplex construct ACGGCUCGAGCAGCGACAA (Dharmacon Inc, IL, USA) was transduced by electroporation c-maf (Amaxa, K ln, Germany) using nucleofaction. We also used Dharmacon s negative control siRNA (ON-TARGETplus siCONTROL ö '
Non-Targeting siRNA) as control. RPMI8226 and LP1 HMCL were electroporated using respectively the programs T-001 or A-023 and the T solution according to the manufacturer s instructions.
'
Real-time RT-PCR
Total RNA was converted to cDNA using the Superscript II reverse transcriptase (Invitrogen, Cergy Pontoise, France). The assays-on-demand primers and probes and the Man Universal Master Mix were used according to the manufacturer s instructions Taq 
TACI influences cexpression maf
In order to determine whether signaling via TACI could induce expression, we exposed the XG-13 and XG-20 TACI HMCL, c-maf 005). The expression of was also reduced c-maf
by 35 ( .005) and 28 ( .01) in these 2 HMCL as well as that of (39 of inhibition in RPMI8226, .006 and 27 % P = % P = integrin beta7
( ). P = Figure 4C As RPMI8226 and LP1 could be nucleotransfected with siRNA, unlike XG HMCL, we used these tow cell lines to investigate further the link between TACI activation and c-maf expression. The nucleofection with c-maf siRNA significantly ( .001) decreases the P = expression of (55 and 45 in RPMI8226 and LP1 HMCL, respectively) as well as the expression of (41 and 47 in c-maf % cyclin D2 % RPMI8226 and LP1, respectively) and (40 and 35 in RPMI8226 and LP1, respectively) ( .05) ( ). The c-maf integrin beta7 % P ≤ Figure 4D siRNA nucleofection did not affect expression in these HMCL. Addition of BAFF/APRIL could not reverse the downregulation of TACI and expression induced by the c-maf siRNA ( ). cyclin D2 integrin beta 7 Figure 4E NF-kappaB pathway is activated by BAFF/APRIL stimulation in MMC ( ). We found here that the expression of was not 16 c-maf affected by a peptide inhibitor of the NF-kappaB pathway (SN50), unlike TACI-Fc ( ). This SN50 peptide inhibitor efficiently Figure 5 inhibited NF-kappaB activation in MMC ( Figure S1 in supplementary data) .
Discussion
The aim of this work was to further characterize the role of TACI-expression in MM. We have previously shown that BAFF and APRIL are important growth factors for MMC, and that the respective receptors, namely TACI, BCMA and BAFF-R, show a characteristic expression pattern in MMC. BAFF-R is not expressed ( ) and BCMA is expressed by all primary MMC and HMCL( ). 33 25 MMC expressing only BCMA seems not to be able to bind BAFF/APRIL. Indeed, the ability of HMCL to bind BAFF is strictly restricted to TACI HMCL ( ). Interestingly, the level of TACI expression in primary MMC correlated with a characteristic phenotypic pattern,
namely, TACI MMC with an expression pattern resembling BMPC, and TACI MMC with a plasmablastic expression pattern ( ).
high low 5 13 First we showed that these expression patterns are kept in HMCL. Using GEP determined with Affymetrix microarrays, TACI + HMCL have a gene signature of BMPC, indicative of a dependence on the microenvironment whereas TACI HMCL have a plasmablastic − gene signature. Indeed, an unsupervised clustering shows that TACI HMCL clustered together with BMPC whereas 6 out of 7 TACI given patient. This may be due to a differentiation of the MM tumor , eventually, as the counterpart of the normal plasma cell in vivo differentiation that is poorly known. This might be also due to a proceeding oncogenic process, rendering MMC less dependent on their dependency on the microenvironment for their survival, proliferation and differentiation. When obtaining an HMCL, which is almost only possible in patients with extramedullary proliferation, only one clone of MMC, frozen ion, at a specific stage of dependency on the BM environment, might be selected. 
